What Longeveron Inc.’s Phase 2b results mean for regenerative medicine in aging populations
Longeveron Inc. publishes Phase 2b laromestrocel data in frailty. Explore what it means for stem cell therapy and regulatory next steps.
Medipost raises $140m to fund U.S. Phase III trial of stem cell therapy for knee osteoarthritis
Medipost secures $140M to fund a pivotal U.S. Phase III trial in osteoarthritis. See how this could reshape the future of scalable stem cell therapies.